Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cisplatin | 8 | 2017 | 611 | 1.020 |
Why?
|
| Pharmacogenetics | 7 | 2014 | 456 | 0.790 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2017 | 2494 | 0.670 |
Why?
|
| Proteomics | 2 | 2017 | 268 | 0.550 |
Why?
|
| Quantitative Trait Loci | 7 | 2017 | 632 | 0.550 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 2059 | 0.500 |
Why?
|
| Antineoplastic Agents | 4 | 2017 | 2417 | 0.440 |
Why?
|
| Proteins | 3 | 2014 | 816 | 0.420 |
Why?
|
| Genome-Wide Association Study | 14 | 2017 | 1763 | 0.400 |
Why?
|
| Population Groups | 1 | 2010 | 42 | 0.330 |
Why?
|
| Cell Proliferation | 3 | 2012 | 1754 | 0.330 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2014 | 644 | 0.320 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 305 | 0.310 |
Why?
|
| Cell Line | 9 | 2017 | 2533 | 0.300 |
Why?
|
| Lymphocytes | 2 | 2010 | 489 | 0.290 |
Why?
|
| Nuclear Proteins | 2 | 2013 | 750 | 0.290 |
Why?
|
| Haplotypes | 1 | 2010 | 650 | 0.290 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 2777 | 0.280 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 771 | 0.280 |
Why?
|
| HapMap Project | 5 | 2014 | 47 | 0.270 |
Why?
|
| Apoptosis | 4 | 2014 | 1760 | 0.210 |
Why?
|
| Proteome | 2 | 2014 | 156 | 0.190 |
Why?
|
| Transcription Factors | 3 | 2017 | 1730 | 0.190 |
Why?
|
| Cytosine | 2 | 2014 | 135 | 0.190 |
Why?
|
| Genes | 2 | 2013 | 308 | 0.180 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2013 | 244 | 0.170 |
Why?
|
| Phenotype | 6 | 2014 | 2579 | 0.140 |
Why?
|
| Carboplatin | 4 | 2011 | 330 | 0.140 |
Why?
|
| Colistin | 1 | 2017 | 7 | 0.130 |
Why?
|
| Drug Synergism | 1 | 2017 | 317 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2014 | 138 | 0.120 |
Why?
|
| Gene Expression | 4 | 2014 | 1320 | 0.120 |
Why?
|
| Humans | 20 | 2017 | 96093 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2013 | 307 | 0.110 |
Why?
|
| Genotype | 3 | 2014 | 1882 | 0.110 |
Why?
|
| Genetic Variation | 5 | 2014 | 1423 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2013 | 204 | 0.110 |
Why?
|
| Genome, Human | 3 | 2014 | 824 | 0.110 |
Why?
|
| DNA Modification Methylases | 1 | 2014 | 32 | 0.110 |
Why?
|
| DNA Repair Enzymes | 1 | 2014 | 61 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2017 | 447 | 0.100 |
Why?
|
| Dacarbazine | 1 | 2014 | 101 | 0.100 |
Why?
|
| Homeodomain Proteins | 1 | 2017 | 563 | 0.100 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 63 | 0.100 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 39 | 0.100 |
Why?
|
| Caspase 1 | 1 | 2012 | 20 | 0.100 |
Why?
|
| Salmonella Infections | 1 | 2012 | 18 | 0.090 |
Why?
|
| Cytarabine | 1 | 2013 | 225 | 0.090 |
Why?
|
| Salmonella typhimurium | 1 | 2012 | 32 | 0.090 |
Why?
|
| Methionine | 1 | 2012 | 68 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2014 | 497 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 301 | 0.090 |
Why?
|
| Nigeria | 1 | 2012 | 162 | 0.090 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 92 | 0.090 |
Why?
|
| Genealogy and Heraldry | 1 | 2011 | 13 | 0.090 |
Why?
|
| Transcriptome | 2 | 2014 | 769 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 100 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 847 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2012 | 215 | 0.080 |
Why?
|
| Chromosomes, Human, X | 1 | 2011 | 57 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2014 | 400 | 0.080 |
Why?
|
| Fluorouracil | 1 | 2012 | 555 | 0.080 |
Why?
|
| Platinum | 1 | 2010 | 67 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 1 | 2010 | 126 | 0.080 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 329 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 810 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 554 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2014 | 2473 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 855 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2013 | 841 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2014 | 3581 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2013 | 9173 | 0.050 |
Why?
|
| RNA Interference | 2 | 2014 | 385 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 563 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2013 | 706 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2017 | 237 | 0.030 |
Why?
|
| Neoplasms | 1 | 2012 | 3248 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2014 | 52 | 0.030 |
Why?
|
| Cyclohexylamines | 1 | 2014 | 8 | 0.030 |
Why?
|
| Plicamycin | 1 | 2013 | 9 | 0.030 |
Why?
|
| Quality Control | 1 | 2014 | 125 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 169 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 297 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 313 | 0.020 |
Why?
|
| Azacitidine | 1 | 2014 | 150 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 299 | 0.020 |
Why?
|
| Thionucleosides | 1 | 2012 | 9 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2013 | 99 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2012 | 49 | 0.020 |
Why?
|
| Antibodies | 1 | 2014 | 356 | 0.020 |
Why?
|
| Deoxyadenosines | 1 | 2012 | 25 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 481 | 0.020 |
Why?
|
| Southwestern United States | 1 | 2011 | 7 | 0.020 |
Why?
|
| Capecitabine | 1 | 2012 | 99 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2014 | 286 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2014 | 1083 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 1195 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 279 | 0.020 |
Why?
|
| Child | 2 | 2014 | 7626 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 908 | 0.020 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 39 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 2344 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 992 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 218 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2012 | 282 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 264 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 64 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2010 | 156 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2013 | 683 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 703 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2014 | 983 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1267 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1346 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2014 | 2090 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 553 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 3107 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2010 | 437 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 2480 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1533 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3489 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3927 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 7230 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 7025 | 0.010 |
Why?
|
| Male | 2 | 2012 | 45870 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 12538 | 0.010 |
Why?
|
| Female | 2 | 2012 | 50030 | 0.010 |
Why?
|
| Aged | 1 | 2012 | 20962 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 28914 | 0.010 |
Why?
|
| Middle Aged | 1 | 2012 | 28361 | 0.010 |
Why?
|
| Adult | 1 | 2012 | 28716 | 0.010 |
Why?
|